Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.
Amphix Bio a preclinical stage company developing a new therapeutic modality for regenerative medicine received an Orphan Drug Designation from the US Food and Drug Administration FDA for its lead candidate AMFX
Thermo Fisher Scientific Inc the world leader in serving science today announced an expansion of their strategic partnership with Sanofi to enable additional US drug product manufacturing The terms of the deal were not disclosed
Elix Incan AI drug discovery company with the mission of Rethinking Drug Discovery and the Life Intelligence Consortium Representative Director Yasushi Okuno Headquarters Osaka hereinafter LINC are pleased to announce that for the first time in the...
Aptar Pharma announces its acquisition of the clinical trial materials manufacturing capabilities of Mod Pharma formerly Enteris Biopharma from SWK Holdings This strategic move strengthens Aptars
Biocon Biologics Ltd BBL a fully integrated global biosimilars company and subsidiary of Biocon Ltd BSE code NSE BIOCON today announced that the US Food and Drug Administration FDA has approved Kirsty Insulin Aspartxjhz
Akeso Incis pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial AKHARMONiGI of ivonescimab in firstline treatment for advanced metastatic colorectal cancer mCRC
Senhwa Biosciences Inc a new drug development company focusing on firstinclass therapeutics for oncology rare diseases and infectious diseases today announced that its new drug Pidnarulex CX
Thermo Fisher Scientific announced that the Oncomine Comprehensive Assay Plus is now available on the Ion Torrent Genexus System helping accelerate precision oncology research
The Series B round saw strong participation from both existing and new investors demonstrating high industry confidence in Illimis Therapeutics vision and technology Eight existing investors including DSC Investment
Integrated Biosciences a biotechnology company integrating optogenetics chemistry and AI to discover small molecule therapeutics for agerelated diseases today announced the publication of a landmark study in Cell
